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ABSTRACT
MicroRNAs (miRNAs) are small, non-coding RNAs that
function as post-transcriptional regulators of gene
expression. The deregulated expression of miRNAs is
associated with a variety of diseases, including breast
cancer. In the present study, we found that miR-495
was markedly up-regulated in clinical breast cancer
samples by quantitative real time-PCR (qRT-PCR).
Junctional adhesion molecule A (JAM-A) was predicted
to be a potential target of miR-495 by bioinformatics
analysis and was subsequently veriﬁed by luciferase
assay and Western blotting. JAM-A was found to be
negatively correlated with the migration of breast
cancer cells through loss-of-function and gain-of-
function assays, and the inhibition of JAM-A by miR-
495 promoted the migration of MCF-7 and MDA-MB-231
cells. Furthermore, overexpression of JAM-A could
restore miR-495-induced breast cancer cell migration.
Taken together, our ﬁndings suggest that miR-495
could facilitate breast cancer progression through the
repression of JAM-A, making this miRNA a potential
therapeutic target.
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INTRODUCTION
Breast cancer is the most common malignancy and the
leading cause of cancer death among females worldwide,
accounting for ∼36% of female primary malignant tumors
(Jemal et al., 2011). Although advances in diagnosis such as
regular mammography and appropriately systemic treat-
ments have improved the prognosis (DeSantis et al., 2014),
distant metastases usually occur several years after the
primary breast cancer, causing approximately 90% of breast
cancer mortality (Bendre et al., 2003). Considering that the
precise mechanisms of breast cancer metastasis remain
largely unknown, additional investigation is necessary to
clarify the progression of this phenomenon.
MicroRNAs (miRNAs) are a class of endogenous, non-
coding RNAs with lengths of 18–25 nt (Bartel, 2004). By
base-pairing with 3′-untranslated region (3′-UTR) of mes-
senger RNA (mRNA), miRNAs can repress the expression of
target genes by inhibiting translation or by destabilizing the
mRNA (Bartel, 2009; Fabian et al., 2010). Under normal
circumstances, miRNAs participate in a broad range of bio-
logical processes, such as cell proliferation and differentia-
tion, development, metabolism, immunity and stress
responses (Ambros, 2001). In recent years, the deregulated
expression of miRNAs has been widely reported in many
diseases, especially in cancer (Lu et al., 2005; Osada and
Takahashi, 2007). With an increasing number of target
genes of miRNAs being validated by experimental assays
and veriﬁed in clinical samples, miRNAs have gradually
emerged as a new important regulator of tumorigenesis and
have been found to be involved in various aspects of cancer
progression including tumor metastasis (Lujambio and Lowe,
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2012). For example, miR-10b is speciﬁcally up-regulated in
metastatic breast cancer cells, resulting in the increased
expression of a well-characterized pro-metastatic gene,
RHOC, by inhibiting the translation of HoxD10 (Ma et al.,
2007). Moreover, the expression of miR-206 is selectively
reduced during breast cancer metastasis, and this reduction
is positively correlated with a low metastasis-free survival in
patients (Li et al., 2013; Vimalraj et al., 2013). These ﬁndings
highlight the need for thorough investigations of miRNAs that
are aberrantly expressed during breast cancer progression,
especially miRNAs associated with breast cancer metastasis
(Vimalraj et al., 2013).
In this study, we demonstrated that miR-495 is signiﬁ-
cantly up-regulated in primary breast cancer tissue samples
when compared with noncancerous tissue samples. By
manipulating miR-495 levels in MCF-7 and MDA-MB-231
cells, we proved that miR-495 promotes the mobility of
breast cancer cells. JAM-A was predicted to be a target of
miR-495, which was veriﬁed by luciferase assay and Wes-
tern blotting; the function of JAM-A in breast cancer metas-
tasis was validated by overexpression or knock down of the
JAM-A protein. Finally, the rescued expression of JAM-A
could reverse the observed effects of miR-495. Our study
demonstrates that miR-495 acts as a metastasis promoter
by directly targeting JAM-A, suggesting that miR-495 has
potential therapeutic value for breast cancer treatment.
RESULTS
MiR-495 is up-regulated in clinical breast cancer
specimens and is positively correlated with the mobility
of breast cancer cells
First, the level of miR-495 in clinical breast cancer tissue
samples was determined using quantitative real time-PCR
(qRT-PCR), and we found that the level of miR-495 in breast
cancer tissues was markedly higher than in paired adjacent
normal breast tissues (Fig. 1A), suggesting that miR-495 is
associated with the progression of breast cancer. The level
of miR-495 in two different breast cancer cell lines MCF-7
and MDA-MB-231 cells was then detected, and we found



















































































































































































































































































































Figure 1. The expression of miR-495 was increased in breast cancer tissues and was positively correlated with the mobility
of breast cancer cells. (A) Quantitative real time-PCR analysis of the relative expression of miR-495 in seven pairs of breast cancer
tissue (BCT) and non-cancerous tissue (NCT) samples. (B) Quantitative real time-PCR analysis of the relative expression of miR-495
in breast cancer cell lines MCF-7 and MDA-MB-231 cells. (C) Left panel: Representative image of wound healing assay of MCF-7 and
MDA-MB-231 cells. Right panel: Quantitative analysis of the wound closure rates. (D) Left panel: Representative image of Transwell
assay of MCF-7 and MDA-MB-231 cells. Right panel: Quantitative analysis of the migration rates. *P < 0.05; **P < 0.01.
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cells (Fig. 1B). MDA-MB-231 cells exhibited a higher mobility
in wound healing assays and Transwell assays (Fig. 1C and
1D), indicating that miR-495 was positively correlated with
the mobility of breast cancer cells.
JAM-A is a potential target of miR-495 in breast cancer
cells
The in silico approaches TargetScan (Lewis et al., 2003) and
miRanda (John et al., 2004) were used in combination to
predict target genes of miR-495, and junctional adhesion
molecule A (JAM-A) was identiﬁed as a potential one. The
putative binding sites for miR-495 in the 3′-UTR of JAM-A
mRNA are shown in Fig. 2A. The seed region (the core
sequences that encompass the ﬁrst 2–8 bases of the mature
miRNA) ofmiR-495 perfectly base-pairswith 3′-UTRof JAM-A
mRNA. Furthermore, the miR-495 binding sequences in the
3′-UTRof JAM-AmRNAare highly conserved across species.
To assess whether JAM-A could be regulated by
miR-495, we investigated the effect of miR-495 on JAM-A
AAAA
Homo sapiens           UUA-UUUUCACAUUGAGUUUGUUUA
Pan troglodytes         UUAUUUUUCACAUUGAGUUUGUUUA
Canis familiaris          UUAUUUUUCACAUUGAGUUUGUUUA
Bos taurus                 UUAUUUUUCACAUUGAGUUUGUUUA
JAM-A 
CDS
5′ UTR                                                                     3′ UTR
Binding site      
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Figure 2. JAM-A is a target gene of miR-495 in breast cancer cells. (A) Schematic illustration of the conserved miR-495 binding
sites. The JAM-A 3′-UTR contains one predictedmiR-495 binding sites. The seed regions of miR-495 and the seed-recognizing sites in
the JAM-A 3′-UTR are indicated in red, and all nucleotides in seed-recognizing sites are completely conserved across several species.
(B) Western blotting analysis of JAM-A protein levels in MCF-7 and MDA-MB-231 cells transfected with miR-495 mimic or inhibitor.
(C) Direct recognition of the JAM-A 3′-UTR by miR-495. Fireﬂy luciferase reporters containing either wild-type (WT) or mutant (MUT)
miR-495 binding sites in the JAM-A 3′-UTR were co-transfected into MDA-MB-231 cells with the scrambled negative control RNA,
miR-495mimic or inhibitor. At 24 h post-transfection, the cells were assayed using a luciferase assay kit. The results were calculated as
the ratio of ﬁreﬂy luciferase activity in the miR-495-transfected cells normalized to the control cells. *P < 0.05; **P < 0.01.
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protein level in MCF-7 and MDA-MB-231 cells. As shown in
Fig. 2B, the level of JAM-A protein was reduced by the
induction of miR-495 mimic but signiﬁcantly increased by
transfection with miR-495 inhibitor in both cell lines.
To ascertain whether miR-495 directly regulates JAM-A
expression by binding with JAM-A 3′-UTR, the full-length
3′-UTR of JAM-A was ampliﬁed by PCR and then fused
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Figure 3. JAM-A expression is decreased in breast cancer tissues and is inversely correlated with the mobility of breast
cancer cells. (A) Western blotting analysis and quantiﬁcation of JAM-A protein levels in seven pairs of breast cancer tissue (BCT)
and non-cancerous tissue (NCT) samples. (B) Western blotting analysis of JAM-A protein levels in MCF-7 and MDA-MB-231 cells.
(C) Left panel: Western blotting analysis of JAM-A protein levels in MCF-7 cells transfected with control siRNA or JAM-A siRNA. Right
panel: Western blotting analysis of JAM-A protein levels in MDA-MB-231 cells transfected with control plasmid or JAM-A
overexpression plasmid. (D) Left panel: Representative image of wound healing assay of MCF-7 cells transfected with control siRNA
or JAM-A siRNA. Right panel: Quantitative analysis of the wound closure rates. (E) Left panel: Representative image of Transwell
assay of MDA-MB-231 cells transfected with control plasmid or JAM-A overexpression plasmid. Right panel: Quantitative analysis of
the migration rates. (F) Left panel: Representative image of wound healing assay of MDA-MB-231 cells transfected with control
plasmid or JAM-A overexpression plasmid. Right panel: Quantitative analysis of the wound closure rates. (G) Left panel:
Representative image of Transwell assay of MDA-MB-231 cells transfected with control plasmid or JAM-A overexpression plasmid.
Right panel: Quantitative analysis of the migration rates. *P < 0.05; **P < 0.01.
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The reporter plasmid was transfected into MDA-MB-231 cells
along with a transfection control plasmid (β-gal) and miR-495
mimic or inhibitor. As expected, overexpression of miR-495
resulted in approximately a 20% reduction in luciferase reporter
activity, whereas inhibition of miR-495 resulted in a 1.3-fold
increase in reporter activity comparedwith the cells transfected
withcontrol inhibitor (Fig.2C).Furthermore,we introducedpoint
mutations into the corresponding complementary sites in the
JAM-A3′-UTR toeliminate thepredictedmiR-495binding sites.
This mutated luciferase reporter was unaffected by either the
overexpression or knockdown of miR-495 (Fig. 2C). In con-
clusion, the results demonstrate that miR-495 inhibits JAM-A
expression by binding to the 3′-UTR of JAM-A.
JAM-A expression is decreased in breast cancer
tissues and is inversely correlated with the mobility
of breast cancer cells
MiRNAs are generally thought to have an expression pattern
that is opposite to that of their targets (Olsen and Ambros,
1999). As miR-495 expression was increased in breast cancer
tissue samples, we next investigated whether JAM-A protein
level was decreased. After detecting the protein level of JAM-A
in the same seven pairs of breast cancer and corresponding
noncancerous tissue samples, we found that JAM-A protein
level was dramatically lower in the breast cancer samples
(Fig. 3A).Moreover,wedetermined the level of JAM-Aprotein in
MCF-7 and MDA-MB-231 cells, and higher level of JAM-A
proteinwasdetected inMCF-7cellswhich showeda lower level
of miR-495 (Fig. 3B). These ﬁndings further suggest that the
level of JAM-Aprotein is negatively correlatedwith themiR-495
level and that JAM-A expression is regulated by miR-495.
As an adhesion molecule participating in comprising tight
junctions, JAM-A was reported to be associated with metasta-
sis of breast cancer cells; however, thereare conﬂicting reports.
For example, Naik et al. (Naik et al., 2008) and Wang et al.
(Wang and Lui, 2012) reported that attenuation of JAM-A con-
tributes to breast cancer cell invasion, whereasMcSherry et al.
revealed that JAM-A drives breast cancer cell migration
(McSherryet al., 2011).To furtherelucidate the functionof JAM-A
in regulating the mobility of breast cancer cells, loss-of-func-
tion assay was performed by transfecting an siRNA against
JAM-A into MCF-7 cells. The left panel of Fig. 3C shows that
the protein level of JAM-A was knocked-down in MCF-7 cells
with JAM-A siRNA. Then, wound healing and Transwell
assays were used to investigate MCF-7 cell migration. Within
24 h,MCF-7 cells with a lower level of JAM-A protein occupied
approximately 46%of thewound, andMCF-7 cells with control
siRNA covered approximately 31% of the wound, indicating
that knockdown of JAM-A promoted the mobility of MCF-7
cells (Fig. 3D). Similarly, Transwell assays showed that more
MCF-7 cells migrated through the porous membrane when
JAM-A expression was inhibited by siRNA (Fig. 3E).
Gain-of-function assay was also conducted by transfect-
ing JAM-A cDNA plasmid into MDA-MBA-231 cells; the
increase in JAM-A protein is shown in the right panel of
Fig. 3C. As expected, overexpression of JAM-A undermined
the migration capability of MDA-MB-231 cells, as demon-
strated by wound healing and Transwell assays (Fig. 3F and
3G). Altogether, JAM-A was found to be down-regulated in
breast cancer and to negatively regulate the mobility of
breast cancer cells.
MiR-495 induces breast cancer cell migration
by targeting JAM-A
After establishing that JAM-A is involved in the migration of
breast cancer cells, the biological signiﬁcance of miR-495 in
breast cancer was then investigated. As shown by wound
healing assays in Fig. 4A, more MCF-7 cells migrated into the
scratch on the cell monolayer when transfected with miR-495
mimic; consistently, knockdown of miR-495 by miRNA inhibi-
tor showed the opposite effects. The same biological function
of miR-495 was found in MDA-MB-231 cells (Fig. 4C). In
addition, Transwell assays revealed a signiﬁcant increase in
cells migrating through the membrane when MCF-7 cells and
MDA-MB-231 cells were transfected with miR-495 mimic
(Fig. 4B and 4D). As anticipated, the mobility of MCF-7 and
MDA-MB-231 cells was clearly inhibited by transfection with
miR-495 inhibitor, shown by Fig. 4B and 4D, respectively.
To further conﬁrm that the effects of miR-495 are medi-
ated by repression of JAM-A in breast cancer cells, knock-
down of JAM-A in MCF-7 cells by miR-495 mimic was
restored by transfecting JAM-A cDNA vector, the expression
of which is not regulated by miR-495 due to its lack of the
3′-UTR (Fig. 5A). Compared with the cells transfected with
miR-495 mimic and control vector, MCF-7 cells transfected
with miR-495 mimic and JAM-A vector exhibited impaired
migration ability (Fig. 5B and 5C). Moreover, JAM-A siRNA
was transfected into MDA-MB-231 cells to counteract the
increase of JAM-A protein caused by miR-495 inhibi-
tor (Fig. 5D). Fig. 5E and 5F show that the inhibition of
MDA-MB-231 cell migration by miR-495 inhibitor can be
reversed by JAM-A siRNA. Taken together, these results
demonstrated that miR-495 promotes breast cancer cell
migration by inhibiting JAM-A.
DISCUSSION
MiRNAs are a class of small, non-coding RNAs that regulate
the expression of speciﬁc mRNAs by either translational
inhibition or mRNA degradation (Bartel, 2004; Fabian et al.,
2010). More than 50% of miRNAs are reported to be located
in cancer-associated genomic break points (Calin et al.,
2004), and these miRNAs can function as tumor suppressor
genes or oncogenes, depending on the target genes regu-
lated by the miRNA (Croce, 2009). MiR-495 was reported to
act as an oncogene in multiple models of cancer. For
example, up-regulation of miR-495 contributes to lower MAT1
expression and enhanced tumorigenesis in hepatocellular
RESEARCH ARTICLE Minghui Cao et al.
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carcinoma (HCC) and may represent a potential target for
HCC therapy (Yang et al., 2013). In addition, up-regulation of
miR-495 by E12/E47 in breast cancer stem cells promotes
oncogenesis and hypoxia resistance via the down-regulation
of E-cadherin and REDD1 (Hwang-Verslues et al., 2011).
However, miR-495 was also shown to suppress tumorigen-
esis in different types of cancer. For example, miR-495
functions as a tumor suppressor by targeting essential leu-
kemia-related genes in MLL-rearranged leukemia (Jiang
et al., 2012) and by down-regulating cyclin-dependent kinase
6 in glioblastoma multiforme cells (Chen et al., 2013). More-
over, miR-495 inhibits the migration of gastric cancer cells
and lung cancer cells by targeting PRL-3 and MTA 3,
respectively (Chu et al., 2014; Li et al., 2012). Although the
function of miR-495 is still controversial in different types of
cancer, in this study, we found that the expression of miR-495
was up-regulated in clinical breast cancer samples, indicating
that miR-495 may be associated with the progression of
breast cancer.
Breast cancer cell line MCF-7 was classiﬁed into luminal
A subtype, which exhibited a characteristic epithelial cob-
blestone-like morphology with high expression of cell-cell
adhesion molecules such as E-cadherin, and has been
identiﬁed as a representative breast cancer cell line with low-
invasive ability. By contrast, MDA-MB-231 was classiﬁed into
claudin-low subtype, and this cell line displayed a high
invasive potential with the characteristics of epithelial-mes-
enchymal transition (EMT), such as expressing a high level
of vimentin (Holliday and Speirs, 2011; Neve et al., 2006). In
the present study, the highly tumorigenic breast cancer cell
line MDA-MB-231 was found to present a high level of
miR-495 when being compared with the less tumorigenic cell
MCF-7. These results suggest that miR-495 is positively
associated with the malignant phenotypes of breast cancer,
including the migration of breast cancer cells, and may serve
as a marker of potential progression of the cancer.
According to the bioinformatics analysis, junction adhe-
sion molecule A (JAM-A, JAM-1, F11 receptor, CD321) was
predicted as a potential target gene of miR-495. Consis-
tently, the level of JAM-A protein was decreased in human
breast cancer tissues, which is coincident with the up-regu-
lation of miR-495. Furthermore, MCF-7 cells with a lower
level of miR-495 expressed a higher level of JAM-A protein
than MDA-MB-231 cells. Moreover, Western blotting ana-
lysis showed that miR-495 inhibits JAM-A translation in
breast cancer cells. We also found that luciferase activity of
the reporter plasmid containing JAM-A 3′-UTR can be
remarkably decreased by miR-495 mimic, while knockdown
of miR-495 in MDA-MB-231 cells resulted in an increase of
luciferase activity. These results proved that miR-495 can
ﬁne-tune the expression of JAM-A through binding to 3′-UTR
of JAM-A.
Originally characterized by the monoclonal antibody F11
on platelets, JAM-A is a type I transmembrane glycoprotein
involved in numerous biological and pathological processes
(Mandell and Parkos, 2005). JAM-A is a cell-adhesion protein
predominantly expressed at the tight junctions of epithelial
cells, including those of the mammary epithelium (Feigin and
Muthuswamy, 2009). Under normal circumstances, JAM-A
participates in the formation of tight junctions (Schneeberger
and Lynch, 2004). The disruption of focal adhesion is asso-
ciated with EMT, which leads to the promotion of cell migra-
tion (Lee et al., 2006). However, the role of JAM-A in the
migration of tumor cells remains a controversial issue. Kos-
hiba et al. reported that JAM-A expression was reduced in
high-grade or advanced endometrial carcinoma and may
constitute a poor prognostic factor (Koshiba et al., 2009). In
addition, Fong et al. found that low JAM-A expression is
associated with metastasis and poor survival in pancreatic
cancer (Fong et al., 2012). Nevertheless, another report
published recently showed that high JAM-A expression in
non-small cell lung cancer (NSCLC) tissues is positively
correlated with NSCLC progression (Zhang et al., 2013).
These data suggest that JAM-A expression is regulated in a
tissue-dependent manner. Additionally, conﬂicting data about
the function of JAM-A in regulating cancer cell migration have
been reported with regard to breast cancer. Naik et al. initially
reported that up-regulation of JAM-A expression decreased
migration and invasion in breast cancer cells, whereas JAM-A
knockdown enhanced invasiveness (Naik et al., 2008). It was
therefore hypothesized that the loss of JAM-A may correlate
with poor clinical prognosis. Similar results were reported by
Wang et al., who demonstrated that transforming growth
factor-β1 (TGF-β1) induced breast cancer cell invasion by
down-regulating JAM-A expression (Wang and Lui, 2012).
However, McSherry and colleagues reported that the
expression of JAM-A is positively correlated with poor prog-
nosis in invasive breast cancer patients, indicating that JAM-A
promotes cell motility in breast cancer by activating Rap 1
GTPase (McSherry et al., 2011). In our study, loss-of-function
assay using MCF-7 cells transfected with JAM-A siRNA
showed that knockdown of JAM-A promotes the migration of
breast cancer cells, whereas gain-of-function assay by
overexpressing JAM-A in MDA-MB-231 cells showed that
s Figure 4. Effects of miR-495 on breast cancer cell migra-
tion. (A) Left panel: Representative image of wound healing
assay of MCF-7 cells transfected with control mimic, miR-495
mimic, control inhibitor or miR-495 inhibitor. Right panel:
Quantitative analysis of the wound closure rates. (B) Left panel:
Representative image of Transwell assay of MCF-7 cells
transfected with control mimic, miR-495 mimic, control inhibitor
or miR-495 inhibitor. Right panel: Quantitative analysis of the
migration rates. (C) Left panel: Representative image of wound
healing assay of MDA-MB-231 cells transfected with control
mimic, miR-495 mimic, control inhibitor or miR-495 inhibitor.
Right panel: Quantitative analysis of the wound closure rates.
(D) Left panel: Representative image of Transwell assay of
MDA-MB-231 cells transfected with control mimic, miR-495
mimic, control inhibitor or miR-495 inhibitor. Right panel: Quan-
titative analysis of the migration rates. *P < 0.05; **P < 0.01.
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JAM-A overexpression attenuates migration. These results
suggest the role of JAM-A as a negative regulator of migra-
tion in breast cancer cells.
Regarding the mechanisms of the down-regulation of
JAM-A protein in breast cancer, previous report showed that
TGF-β1 inhibits JAM-A gene transcription via the activation
of Smads (Wang and Lui, 2012). Considering that the 3′-UTR
of human JAM-A is as long as 3.6 kb, we hypothesized that
JAM-A expression may be down-regulated by miRNAs, such
as miR-495, in breast cancer; indeed, a negative correlation
between the expression of miR-495 and JAM-A was estab-
lished in the present study. The overexpression of miR-495
promoted the mobility of breast cancer cells by down-regu-
lating JAM-A. Additionally, the restoration of JAM-A protein
by expressing JAM-A cDNA vector, which lacked 3′-UTR
and thus not regulated by miRNAs, reversed the migration
promotion exerted by miR-495, further conﬁrming that
miR-495 regulates the migration of breast cancer cells by
targeting JAM-A. Moreover, comparison of the mobility of
MDA-MB-231 cells transfected with miR-495 inhibitor plus
control siRNA or miR-495 inhibitor plus JAM-A siRNA
revealed that miR-495 inhibitor down-regulated the migration
of breast cancer cells by regulating JAM-A expression.
Taken together, our data reveal a new role for miR-495
as an oncogenic miRNA in breast carcinogenesis. Identiﬁ-
cation of the miR-495-targeting JAM-A pathway provides a





were collected from the Afﬁliated Drum Tower Hospital of Nanjing Uni-
versity Medical School and the Afﬁliated Jinling Hospital of Southern
Medical University (Nanjing, China). Written informed consent was
obtained from all patients. The Ethics Committee of Nanjing University
approved all aspects of this study. The tissue fragments were immedi-
ately frozen in liquid nitrogen at the time of surgery and stored at−80°C.
The clinical features of the patients are listed in Table S1.
RNA isolation and quantitative real time-PCR (qRT-PCR)
Total RNA was extracted from cultured cells or tissue samples with
TRIzol Reagent (Invitrogen) according to the manufacturer’s
instructions. Assays for miR-495 quantiﬁcation were conducted by
using gene-speciﬁc TaqMan miRNA Assay Probes (Applied Biosys-
tems, Foster City, CA). After the real-time PCR reaction, the cycle
threshold (CT) data were determined using ﬁxed threshold settings;
the mean CT was determined from triplicate PCRs. A comparative CT
method was used to compare each condition to the controls. The U6
snRNA was used as an internal control, and the relative amount of
miR-495 normalized to U6 was calculated using the equation 2−ΔΔCT,
where ΔΔCT = (CT miR-495 − CT U6)target − (CT miR-495 − CT U6)control.
Overexpression or knockdown of JAM-A
A full-length JAM-A cDNA expression plasmid (EX-U0777-M02)
lacking the 3′-UTR was purchased from GeneCopoeia (Rockville,
MD, USA), and the empty plasmid served as the negative control.
The siRNA sequence targeting human JAM-A mRNA was designed
and synthesized by RiboBio (Guangzhou, China), with a scrambled
siRNA included as negative control. The sequences of the JAM-A
siRNA were as follows: 5′-GGAUAGUGAUGCCUACGAAdTdT-3′
(sense); 5′-dTdTCCUAUCACUACGGAUGCUU-3′ (antisense).
The JAM-A overexpression plasmid or siRNA was transfected
into MCF-7 or MDA-MB-231 cells using Lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s instructions. The concen-
tration for transfection of JAM-A cDNA plasmid or siRNA was
0.05 µg/mL or 50 nmol/L, respectively.
Overexpression or knockdown of miR-495
The overexpression or knockdown of miR-495 was accomplished by
transfecting cells with a synthetic miR-495 mimic or inhibitor pur-
chased from Genephama (Shanghai, China). The transfection con-
centrations were 50 nmol/L for the miR-495 mimic and 200 nmol/L
for the miR-495 inhibitor, which were also adopted when the control
mimic or inhibitor was transfected.
Western blotting
Western blotting was carried out as described previously (Cao et al.,
2014). An anti-JAM-A antibody was obtained from Epitomics
(#1840-1, Burlingame, CA, USA). An antibody against GAPDH, as
the control, was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
s Figure 5. MiR-495 induces breast cancer cell migration by
targeting JAM-A. (A) Western blotting analysis of the protein
levels of JAM-A in MCF-7 cells transfected with control mimic
plus control plasmid, miR-495 mimic plus control plasmid or
miR-495 mimic plus JAM-A overexpression plasmid. (B) Left
panel: Representative image of wound healing assay of MCF-7
cells transfected with control mimic plus control plasmid,
miR-495 mimic plus control plasmid or miR-495 mimic plus
JAM-A overexpression plasmid. Right panel: Quantitative ana-
lysis of the wound closure rates. (C) Top panel: Representative
image of Transwell assay of MCF-7 cells transfected with
control mimic plus control plasmid, miR-495 mimic plus control
plasmid or miR-495 mimic plus JAM-A overexpression plasmid.
Bottom panel: Quantitative analysis of the migration rates.
(D) Western blotting analysis of the protein levels of JAM-A in
MDA-MB-231 cells transfected with control inhibitor plus control
siRNA, miR-495 inhibitor plus control siRNA or miR-495
inhibitor plus JAM-A siRNA. (E) Left panel: Representative
image of wound healing assay of MDA-MB-231 cells transfec-
ted with control inhibitor plus control siRNA, miR-495 inhibitor
plus control siRNA or miR-495 inhibitor plus JAM-A siRNA.
Right panel: Quantitative analysis of the wound closure rates.
(F) Left panel: Representative image of Transwell assay of
MDA-MB-231 cells transfected with control inhibitor plus control
siRNA, miR-495 inhibitor plus control siRNA or miR-495
inhibitor plus JAM-A siRNA. Right panel: Quantitative analysis
of the migration rates. *P < 0.05; **P < 0.01.
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The entire 3′-UTR of human JAM-A was ampliﬁed by PCR using
human genomic DNA as the template, and the PCR products were
inserted into the p-MIR-reporter plasmid (Ambion, Austin, TX, USA).
The insertion was conﬁrmed by sequencing. To test the binding
speciﬁcity, the sequences that interact with the miR-495 seed
sequence were mutated (from GUUUGUU to CAAACAA), and the
mutant JAM-A 3′-UTR was inserted into an equivalent luciferase
reporter plasmid. For the luciferase reporter assay, MDA-MB-231
cells were seeded in 24-well plates, and each well was transfected
with 0.2 µg of luciferase reporter plasmid, 0.4 µg of β-galactosidase
(β-gal) expression plasmid and 40 pmol of miR-495 mimic, 120 pmol
of miR-495 inhibitor or scrambled negative control RNAs using
Lipofectamine 2000 (Invitrogen). The β-gal plasmid was used as the
transfection control. At 24 h after transfection, the cells were har-
vested and analyzed for luciferase activity using luciferase assay
kits (Promega, Madison, WI, USA).
Wound healing assays
Cell migration was assessed in classical wound healing assays with
some modiﬁcations (Rodriguez et al., 2005). Brieﬂy, cells were
seeded in 6-well plates and transfected when they were attached.
After transfection, the cells were allowed to culture to conﬂuence.
Then, the cell layer was gently wounded using a plastic pipette tip
(P200) and rinsed with PBS before the culture medium was
replaced. The bottom of the wells was marked to indicate where the
initial images of the wounded area were captured. At 24 h of incu-
bation, images (10×) of the same areas were recorded using a
photomicroscope (BX51 Olympus, Japan), and closure of the
wounds was processed using Image-Pro Plus 6.0.
Transwell assays
The migration ability of cells was also tested in a Transwell Boyden
Chamber (6.5 mm, Costar, USA). The polycarbonate membranes
(8-μm pore size) on the bottom of the upper compartment of the
Transwells were coated with 1% human ﬁbronectin (R&D Systems
1918-FN, USA). At 24 h after transfection, the cells were harvested,
counted and suspended in FBS-free DMEM medium. Then, 3 × 104
cells in 200 µL DMEM medium were added to each upper chamber;
0.6 mL of DMEM with 10% FBS was added to the lower compart-
ment, and the Transwell-containing plates were incubated at 37°C
and 5% CO2 for 8 h. After incubation, the cells that had entered the
lower surface of the membrane were ﬁxed with 4% paraformalde-
hyde for 20 min at room temperature, washed 3 times with distilled
water and stained with 0.1% crystal violet in 0.1 mol/L borate and 2%
ethanol for 15 min at room temperature. The non-migrant cells
remaining on the upper surface of the ﬁlter membrane were scraped
off gently with a cotton swab. The lower surfaces (with migrant cells)
were captured using a photomicroscope (5 ﬁelds per chamber)
(BX51 Olympus, Japan), and the cells were counted blindly.
Statistical analysis
All images of Western blotting, wound healing assays and Transwell
assays are representative of at least three independent experi-
ments. Quantitative RT-PCR and the luciferase reporter assay were
performed in triplicate, and each experiment was repeated at least
three times. The results are presented as the mean ± SD. The dif-
ferences between groups were calculated using Student’s t-test, and
P < 0.05 was deﬁned as statistically signiﬁcant.
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